Klivira
Request demo

Streamlining Tysabri Prior Authorization for Orthopedics

Navigating Tysabri prior authorization for orthopedics presents unique challenges, particularly when managing patients with complex co-morbid conditions such as Multiple Sclerosis or Crohn's disease.

Orthopedic practices frequently treat patients with underlying systemic inflammatory or neurological conditions that necessitate high-cost biologic therapies like Tysabri (natalizumab). While Tysabri is not an orthopedic drug, understanding its prior authorization landscape is critical for comprehensive patient management, ensuring continuity of care, and coordinating elective procedures without unnecessary delays.

Tysabri's Role in Complex Orthopedic Patient Management

Tysabri, an alpha-4 integrin inhibitor, is primarily indicated for relapsing forms of Multiple Sclerosis (MS) and Crohn's disease. Patients with these conditions often require orthopedic care due to mobility impairments, spasticity, falls, or inflammatory arthropathy. While orthopedic surgeons do not typically prescribe Tysabri, they must be acutely aware of a patient's ongoing Tysabri therapy when planning interventions, assessing surgical risks, or coordinating care, as the PA status of such critical medications can impact overall treatment pathways.

Key PA Considerations for Tysabri in Orthopedic Patient Care

  • **Diagnosis Confirmation:** Payer policies for Tysabri consistently require robust documentation confirming the diagnosis of MS (e.g., McDonald criteria, MRI evidence) or Crohn's disease (e.g., endoscopy, biopsy).
  • **Prior Failed Therapies:** Approval often hinges on documented failure or intolerance to specific first-line or alternative therapies, such as interferons or glatiramer acetate for MS, or anti-TNF agents for Crohn's.
  • **REMS Program Compliance:** Tysabri is subject to a Risk Evaluation and Mitigation Strategy (REMS), the TOUCH Prescribing Program, due to the risk of Progressive Multifocal Leukoencephalopathy (PML). Enrollment and adherence to this program are critical for PA approval.
  • **Clinical Justification:** Documentation must clearly articulate the patient's disease activity, severity, and the rationale for Tysabri over other available treatments, aligning with guidelines from bodies like the American Academy of Neurology (AAN) or the American College of Gastroenterology (ACG).

Navigating Orthopedic PA Challenges with Co-morbid Biologic Therapy

The presence of a complex biologic like Tysabri adds layers of complexity to standard orthopedic prior authorization processes. For instance, payers' stringent requirements for conservative-care trials for joint replacement or spine surgery must be met, but the patient's overall health status, including their MS or Crohn's, may influence the feasibility or duration of such trials. Furthermore, considerations around immunosuppression for surgical candidates on Tysabri necessitate careful coordination and often impact the timing and type of orthopedic intervention, requiring a holistic approach to PA submissions.

Common Denial Triggers for Tysabri in an Orthopedic Context

  • **Incomplete Documentation:** Gaps in evidence of diagnosis, disease activity, or prior failed therapies are frequent causes of denial for Tysabri, which can disrupt a patient's overall care plan.
  • **Non-compliance with REMS:** Failure to document adherence to the TOUCH Prescribing Program for Tysabri will result in PA denial, directly impacting treatment continuity.
  • **Insufficient Conservative Care for Orthopedic Procedures:** Even with a complex medical history, payers for orthopedic procedures (e.g., CPT 27447, CPT 22612) will rigorously review documentation of failed conservative care, a common orthopedic denial pattern.
  • **Imaging-Symptom Correlation Gaps:** For advanced imaging (e.g., MRI of spine/joints), denials can occur if clinical findings are not clearly correlated with imaging-indicated pathology, often routed through specialty benefit-management vendors.
  • **Site-of-Service Mismatch:** Payer policies may dictate specific sites for certain orthopedic procedures (e.g., ASC vs. hospital), leading to denials if the requested setting does not align.

Klivira's Solution for Integrated Prior Authorization Management

Klivira's platform empowers orthopedic practices to manage the intricate PA landscape for all patients, including those on complex biologics like Tysabri. By integrating with EMRs via SMART on FHIR and connecting to payer portals and X12 278 transactions, Klivira automates the submission and tracking of orthopedic PAs. Our system's AAOS-guideline-aware conservative-care logic, combined with multi-step PA cascade orchestration for imaging-then-surgery sequences, ensures that even with the added complexity of a patient's Tysabri therapy, all necessary documentation is gathered and submitted efficiently, minimizing care delays and administrative burden.

Frequently asked questions

Why would an orthopedic practice need to understand Tysabri prior authorization?

Orthopedic practices frequently manage patients with co-morbid conditions like MS or Crohn's disease who are on Tysabri. Understanding Tysabri's PA status and requirements is crucial for coordinating overall patient care, assessing surgical risks, and ensuring that any orthopedic interventions do not conflict with or delay the patient's ongoing critical biologic therapy.

What documentation is typically required for Tysabri PA?

Common documentation includes confirmed diagnosis of MS or Crohn's, evidence of prior failed therapies, adherence to the Tysabri TOUCH Prescribing Program, and detailed clinical justification aligning with established medical guidelines. This information is typically provided by the prescribing neurologist or gastroenterologist.

How does Klivira help manage PAs for orthopedic patients on complex biologics?

Klivira automates the PA process for orthopedic procedures and imaging, integrating with EMRs to pull necessary clinical data. While Klivira does not directly manage the Tysabri PA itself (which is handled by the prescribing specialist), our platform helps orthopedic practices efficiently manage *their* PAs, ensuring that all documentation, including considerations for complex patient profiles, is complete and submitted promptly to avoid delays in care.

Are there specific payer policies for Tysabri that impact orthopedic care coordination?

Yes, payers have specific medical policies for Tysabri that outline diagnostic criteria, step therapy requirements, and adherence to the TOUCH program. While these policies directly govern Tysabri approval, orthopedic practices must be aware of them to understand potential care coordination challenges, especially if a patient's Tysabri therapy is paused or denied, which could impact the timing or safety of orthopedic procedures.

What role does conservative care play when a patient is on Tysabri for a co-morbid condition?

Conservative care remains a critical component for orthopedic PA approvals, even for patients on Tysabri. Payers will still require documentation of failed conservative therapies (e.g., physical therapy, NSAIDs) for procedures like joint replacement or spine surgery. The challenge lies in documenting the conservative care trial while also managing the patient's complex underlying condition and its associated biologic therapy.

Related coverage

Other tysabri prior authorization by payer

Other tysabri prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo